Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling

Biochemical Pharmacology

Volumn 87, Issue 4, 2014, Pages 571-578

  Koval, A V ^a   Vlasov, P ^b,c   Shichkova, P ^d   Khunderyakova, S ^e   Markov, Y ^f   Panchenko, J ^d   Volodina, A ^g   Kondrashov, F A ^b,c,h   Katanaev, V L ^a,i  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^e Municipal Budget Institution of General Education Gymnasium Pushchino   (Russian Federation)

^f NATIONAL RESEARCH UNIVERSITY HIGHER SCHOOL OF ECONOMICS   (Russian Federation)

^g KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

ⁱ INSTITUTE OF PROTEIN RESEARCH   (Russian Federation)

Author keywords

Breast cancer; Clofazimine; In silico screening; Wnt signaling

Indexed keywords

BREAST CANCER; CLOFAZIMINE; IN SILICO SCREENING; WNT SIGNALING;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CLOFAZIMINE; CRYSTALLOGRAPHY, X-RAY; GROWTH INHIBITORS; HEK293 CELLS; HUMANS; LEPROSTATIC AGENTS; MICE; TRIPLE NEGATIVE BREAST NEOPLASMS; WNT SIGNALING PATHWAY; WNT3A PROTEIN;

EID: 84893754602     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.12.007     Document Type: Article

References (44)

1. N. Novac Challenges and opportunities of drug repositioning Trends Pharmacol Sci 34 2013 267 272
2. M. Boolell, M.J. Allen, S.A. Ballard, S. Gepi-Attee, G.J. Muirhead, and A.M. Naylor et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction Int J Impot Res 8 1996 47 52
3. D. Weber, K. Rankin, M. Gavino, K. Delasalle, and R. Alexanian Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
4. B.T. MacDonald, K. Tamai, and X. He Wnt/β-catenin signaling: components, mechanisms, and diseases Dev Cell 17 2009 9 26
5. N. Barker, and H. Clevers Mining the Wnt pathway for cancer therapeutics Nat Rev Drug Discov 5 2006 997 1014 (Pubitemid 44835127)
6. L. Yang, X. Wu, Y. Wang, K. Zhang, J. Wu, and Y.C. Yuan et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer Oncogene 30 2011 4437 4446
7. C.Y. Janda, D. Waghray, A.M. Levin, C. Thomas, and K.C. Garcia Structural basis of Wnt recognition by Frizzled Science 2012
8. F. Verkaar, and G.J.R. Zaman New avenues to target Wnt/β-catenin signaling Drug Discov Today 16 2011 35 41
9. A. Koval, and V.L. Katanaev Platforms for high-throughput screening of Wnt/Frizzled antagonists Drug Discov Today 17 2012 1316 1322
10. P. Gurfinkel, J.C. Pina, and M. Ramos-e-Silva Use of clofazimine in dermatology J Drugs Dermatol 8 2009 846 851
11. O. Trott, and A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading J Comput Chem 31 2010 455 461
12. A. Koval, and V.L. Katanaev Wnt3a stimulation elicits G-protein-coupled receptor properties of mammalian Frizzled proteins Biochem J 433 2011 435 440
13. C. Mosimann, G. Hausmann, and K. Basler The role of parafibromin/hyrax as a nuclear Gli/Ci-interacting protein in hedgehog target gene control Mech Dev 126 2009 394 405
14. B.W. Dyer, F.A. Ferrer, D.K. Klinedinst, and R. Rodriguez A noncommercial dual luciferase enzyme assay system for reporter gene analysis Anal Biochem 282 2000 158 161 (Pubitemid 30409441)
15. Shibamoto, K. Higano, R. Takada, F. Ito, M. Takeichi, and S. Takada Cytoskeletal reorganization by soluble Wnt-3a protein signalling Genes Cells 3 1998 659 670 (Pubitemid 28557207)
16. C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, and A. Frolkis et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucl Acids Res 39 2011 1035 1041
17. B.K. Atwood, J. Lopez, J. Wager-Miller, K. Mackie, and A. Straiker Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis BMC Genomics 2011 12
18. J.P. Dijksterhuis, J. Petersen, and G. Schulte WNT/Frizzled signaling: receptor-ligand selectivity with focus on FZD-G protein signaling and its physiological relevance Br J Pharmacol 2013 n/a n/a
19. A. Koval, V. Purvanov, D. Egger-Adam, and V.L. Katanaev Yellow submarine of the Wnt/Frizzled signaling: submerging from the G protein harbor to the targets Biochem Pharmacol 82 2011 1311 1319
20. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development PNAS 93 1996 8455 8459 (Pubitemid 26269579)
21. E.Y. Lasfargues, and L. Ozzello Cultivation of human breast carcinomas J Nat Cancer Inst 21 1958 1131 1147
22. T.D. King, M.J. Suto, and Y. Li The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer J Cell Biochem 113 2012 13 18
23. D.E. Nix, R.D. Adam, B. Auclair, T.S. Krueger, P.G. Godo, and C.A. Peloquin Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid Tuberculosis 84 2004 365 373 (Pubitemid 39451903)
24. R.E. Mansfield Tissue concentrations of clofazimine (B663) in man Am J Trop Med Hyg 23 1974 1116 1119
25. M.V. Jadhav, A.G. Sathe, S.S. Deore, P.G. Patil, N.G. Joshi, and N.G. Joghi Tissue concentration, systemic distribution and toxicity of clofazimine - an autopsy study Indian J Pathol Microbiol 47 2004 281 283 (Pubitemid 41656646)
26. M.Y. Sherman, L. Meng, M. Stampfer, V.L. Gabai, and J.A. Yaglom Oncogenes induce senescence with incomplete growth arrest and suppress the DNA damage response in immortalized cells Aging Cell 10 2011 949 961
27. M.R. Stampfer, J. Garbe, G. Levine, S. Lichtsteiner, A.P. Vasserot, and P. Yaswen Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor?. growth inhibition in p16INK4A(-) human mammary epithelial cells PNAS 98 2001 4498 4503 (Pubitemid 32295005)
28. A. Gazit, A. Yaniv, A. Bafico, T. Pramila, M. Igarashi, and J. Kitajewski et al. Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response Oncogene 18 1999 5959 5966 (Pubitemid 29535007)
29. H.G. Pálmer, J.M. González-Sancho, J. Espada, M.T. Berciano, I. Puig, and J. Baulida et al. Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling J Cell Biol 154 2001 369 388
30. N. Pendás-Franco, Ó. Aguilera, F. Pereira, J.M. González-Sancho, and A. Muñoz Vitamin D and Wnt/(-catenin Pathway in colon cancer: role and regulation of DICKKOPF genes Anticancer Res 28 2008 2613 2623
31. Y. Matsuda, and M. Fukumoto Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled Med Mol Morphol 44 2011 183 189
32. A. Lachenmayer, C. Alsinet, R. Savic, L. Cabellos, S. Toffanin, and Y. Hoshida et al. Wnt-Pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib Clin Cancer Res 18 2012 4997 5007
33. A.P. Kouzmenko, K.-I. Takeyama, S. Ito, T. Furutani, S. Sawatsubashi, and A. Maki et al. Wnt/beta-catenin and estrogen signaling converge in vivo J Biol Chem 279 2004 40255 40258 (Pubitemid 39287607)
34. P. Thomas, Y. Pang, E.J. Filardo, and J. Dong Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells Endocrinology 146 2005 624 632 (Pubitemid 40129818)
35. Hormone Replacement Therapy and Cancer Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology 2001 Hormone Replacement Therapy and Cancer 15 453 465
36. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713-27.
37. V.C. Barry, J.G. Belton, M.L. Conalty, J.M. Denneny, D.W. Edward, and J.F. O'Sullivan et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity Nature 179 1957 1013 1015
38. M.C. Cholo, H.C. Steel, P.B. Fourie, W.A. Germishuizen, and R. Anderson Clofazimine: current status and future prospects J Antimicrob Chemother 2011
39. C.E.J. Van Rensburg, R. Anderson, and J.F. O'Sullivan Riminophenazine compounds: pharmacology and anti-neoplastic potential Crit Rev Oncol/Hematol 25 1997 55 67 (Pubitemid 27138048)
40. R. O'Connor, J.F. O'Sullivan, and R. O'Kennedy The pharmacology, metabolism, and chemistry of clofazimine Drug Metab Rev 27 1995 591 614 (Pubitemid 26032119)
41. C.E. Van Rensburg, A.M. Van Staden, and R. Anderson The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms Cancer Res 53 1993 318 323 (Pubitemid 23031843)
42. R.M. Sri-Pathmanathan, J.A. Plumb, and K.C. Fearon Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung-cancer cell line in vitro and in vivo Int J Cancer 56 1994 900 905 (Pubitemid 24102760)
43. L.R. Howe, and A.M.C. Brown Wnt signaling and breast cancer Cancer Biol Ther 3 2004 36 41
44. H.J. Lee, X. Zhang, and J.J. Zheng Inhibiting the Wnt signaling pathway with small molecules Targeting Wnt Pathway Cancer 2011 183 209